JP2005505521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505521A5 JP2005505521A5 JP2003516484A JP2003516484A JP2005505521A5 JP 2005505521 A5 JP2005505521 A5 JP 2005505521A5 JP 2003516484 A JP2003516484 A JP 2003516484A JP 2003516484 A JP2003516484 A JP 2003516484A JP 2005505521 A5 JP2005505521 A5 JP 2005505521A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- following formula
- polar
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 31
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 14
- -1 lipid compound Chemical class 0.000 claims 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 10
- 239000002502 liposome Substances 0.000 claims 8
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- 150000001784 cerebrosides Chemical class 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 150000002314 glycerols Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002759 monoacylglycerols Chemical class 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000008103 phosphatidic acids Chemical class 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims 1
- 150000008106 phosphatidylserines Chemical class 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 0 **(C1OC1N)C(O)=* Chemical compound **(C1OC1N)C(O)=* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0118517.2A GB0118517D0 (en) | 2001-07-30 | 2001-07-30 | Compound |
| PCT/GB2002/003488 WO2003011252A1 (en) | 2001-07-30 | 2002-07-29 | Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505521A JP2005505521A (ja) | 2005-02-24 |
| JP2005505521A5 true JP2005505521A5 (enExample) | 2006-01-05 |
Family
ID=9919439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003516484A Pending JP2005505521A (ja) | 2001-07-30 | 2002-07-29 | 極性成分および非極性成分を含む脂質を含む医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040219202A1 (enExample) |
| EP (1) | EP1411898A1 (enExample) |
| JP (1) | JP2005505521A (enExample) |
| CN (1) | CN100457088C (enExample) |
| AU (1) | AU2002317402B2 (enExample) |
| CA (1) | CA2451868A1 (enExample) |
| GB (1) | GB0118517D0 (enExample) |
| RU (1) | RU2294738C2 (enExample) |
| WO (1) | WO2003011252A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO328803B1 (no) * | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| CA2490121C (en) * | 2002-06-20 | 2013-01-08 | Ic Vec Limited | Modified phospholipids |
| DE10236146A1 (de) * | 2002-07-31 | 2004-02-19 | Basf Coatings Ag | Beschichtungsstoff, Verfahren zu seiner Herstellung und seine Verwendung |
| US20090220583A1 (en) * | 2005-06-09 | 2009-09-03 | Lena Pereswetoff-Morath | Method and composition for treating inflammatory disorders |
| CA2927045A1 (en) * | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| EP2086508A2 (en) * | 2006-11-03 | 2009-08-12 | MediGene Aktiengesellschaft | Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| EP2105145A1 (en) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
| WO2009129227A1 (en) | 2008-04-17 | 2009-10-22 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| CN105152939A (zh) | 2008-11-10 | 2015-12-16 | 阿尔尼拉姆医药品有限公司 | 用于递送治疗剂的脂质和组合物 |
| RU2394834C1 (ru) * | 2009-06-29 | 2010-07-20 | Учреждение Российской академии наук Институт химической биологии и фундаментальной медицины Сибирского отделения РАН (ИХБФМ СО РАН) | Углеводсодержащие катионные амфифилы, обладающие способностью доставлять нуклеиновые кислоты в клетки млекопитающих |
| WO2013126803A1 (en) * | 2012-02-24 | 2013-08-29 | Protiva Biotherapeutics Inc. | Trialkyl cationic lipids and methods of use thereof |
| CN105163753B (zh) | 2012-06-15 | 2018-12-21 | Pds生物科技公司 | 阳离子脂质疫苗组合物和使用方法 |
| KR102176971B1 (ko) | 2012-07-05 | 2020-11-11 | 타이완 리포좀 캄파니 리미티드 | 관절염의 치료 방법 |
| EP2897639A4 (en) | 2012-09-21 | 2016-05-04 | Frank Bedu-Addo | IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE |
| ES2782360T3 (es) | 2013-08-30 | 2020-09-14 | Univ Dalhousie | Composiciones y procedimientos para la eliminación de tatuajes |
| CA3005251A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| WO2017087685A1 (en) * | 2015-11-20 | 2017-05-26 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0032622B1 (en) * | 1979-12-20 | 1985-08-14 | Dennis Chapman | Polymerisable phospholipids and polymers thereof, methods for their preparation, methods for their use in coating substrates and forming liposomes and the resulting coated substrates and liposome compositions |
| IE912535A1 (en) * | 1990-07-27 | 1992-01-29 | Res Dev Foundation | Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens |
| HUT72326A (en) * | 1993-10-06 | 1996-04-29 | Amgen Inc | Stable protein phospholipid compositions and methods |
| US6187335B1 (en) * | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| NZ506051A (en) * | 1998-02-09 | 2003-08-29 | Bracco Res S | Targeted delivery of biologically active media |
| GB9930533D0 (en) * | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
-
2001
- 2001-07-30 GB GBGB0118517.2A patent/GB0118517D0/en not_active Ceased
-
2002
- 2002-07-29 EP EP02745690A patent/EP1411898A1/en not_active Withdrawn
- 2002-07-29 JP JP2003516484A patent/JP2005505521A/ja active Pending
- 2002-07-29 AU AU2002317402A patent/AU2002317402B2/en not_active Ceased
- 2002-07-29 US US10/484,855 patent/US20040219202A1/en not_active Abandoned
- 2002-07-29 CA CA002451868A patent/CA2451868A1/en not_active Abandoned
- 2002-07-29 WO PCT/GB2002/003488 patent/WO2003011252A1/en not_active Ceased
- 2002-07-29 CN CNB028192850A patent/CN100457088C/zh not_active Expired - Fee Related
- 2002-07-29 RU RU2004106154/15A patent/RU2294738C2/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505521A5 (enExample) | ||
| RU2004106154A (ru) | Фармацевтическая композиция, содержащая липиды, которые несут полярный и неполярный фрагмент | |
| CA2205136C (en) | Improved antiviral prodrugs of phosphonoacids | |
| EP0742789B1 (en) | Pharmaceutically active compounds and liposomes, and methods of use therof | |
| Eibl | Synthesis of glycerophospholipids | |
| US5830430A (en) | Cationic lipids and the use thereof | |
| EP0674646B1 (en) | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use | |
| AU711774B2 (en) | Prodrugs of pharmaceuticals with improved bioavailability | |
| JP2002511406A (ja) | 感染症の治療および予防処置のための有機リン化合物の使用 | |
| JP2001516714A5 (enExample) | ||
| US4734225A (en) | D-mannite derivatives as starting products for the synthesis of phospholipids | |
| US5436234A (en) | Eurcyl, brassidyl and nervonyl derivatives | |
| JP2015519383A5 (enExample) | ||
| KR20010070962A (ko) | 유기 인 화합물 및 이의 용도 | |
| MXPA06013624A (es) | Derivados de amino-propanol. | |
| TW201751B (enExample) | ||
| JP2008519064A5 (enExample) | ||
| CN1088582C (zh) | 能治疗多种疾病具有层状类脂组分的类脂基载体、其组合物及其应用 | |
| AU754862B2 (en) | Use of bisphosphonates for the prevention and treatment of infectious processes | |
| JP2006504635A5 (enExample) | ||
| US20030036533A1 (en) | Phosphorous organic compounds and their use | |
| JP4851946B2 (ja) | 脂質由来ビスホスホン酸 | |
| JP2008528696A5 (enExample) | ||
| JP2007516244A (ja) | 新しいクラスのガンマデルタｔ細胞アクチベーターおよびその使用 | |
| CN1589142A (zh) | 三环－[5.2.1.02.6]－癸－9－基－黄原酸酯的纯立体异构体的制备和由其制成的药物 |